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Abstract
Objectives The aim of this randomized placebo-controlled
trail was to compare the effects of an objectively titrated man-
dibular advancement device (MAD) with those of nasal con-
tinuous positive airway pressure (nCPAP) and an intraoral
placebo device on symptoms of psychological distress in
OSA patients.
Materials and methods In a parallel design, 64 mild/moderate
OSA patients (52.0 ± 9.6 years) were randomly assigned to an
objectively titrated MAD, nCPAP, or an intraoral placebo ap-
pliance. All patients filled out the Symptom Checklist-90-
Revised twice: one before treatment and one after 6 months
of treatment. The Symptom Checklist-90-Revised is a multi-
dimensional symptom inventory designed to measure symp-
tomatic psychological distress over the past week. Linear
mixed model analyses were performed to study differences
between the therapy groups for the different dimensions of
the Symptom Checklist-90-Revised over time.
Results The MAD group showed significant improvements
over time in the dimensions Bsomatization,^ Binsufficiency
of thinking and acting,^ Bagoraphobia,^ Banxiety,^ Bsleeping
problems,^ and Bglobal severity index^ (F = 4.14–16.73,
P = 0.048–0.000). These improvements in symptoms of psy-
chological distress were, however, not significantly different
from those observed in the nCPAP and placebo groups
(P = 0.374–0.953).
Conclusion There is no significant difference between MAD,
nCPAP, and an intraoral placebo appliance in their beneficial
effects on symptoms of psychological distress.
Clinical relevance The improvement in psychological dis-
tress symptoms in mild/moderate OSA patients under MAD
or nCPAP treatment may be explained by a placebo effect.
Keywords Psychology . Psychiatry . Obstructive sleep
apnea .Mandibular . Repositioning . Splint
Introduction
Obstructive sleep apnea (OSA) is characterized by recurrent
obstruction of the upper airway, often resulting in oxygen
desaturation and arousal from sleep [1]. Excessive daytime
sleepiness, snoring, and reduction in cognitive functions are
common symptoms of this condition [1]. OSA patients may
also report symptoms of psychological distress, such as de-
pression and anxiety [2]. Beebe and Gozal [3] suggested that
both intermittent hypoxia and sleep disruption induce dys-
function of the prefrontal regions of the brain cortex, which
may predispose to psychological distress.
Although continuous positive airway pressure (CPAP) has
been proposed as the most effective treatment for severe OSA
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patients, nowadays mandibular advancement devices (MADs)
are considered as a primary treatment option in mild and mod-
erate OSA patients and in patients who do not tolerate CPAP
[4]. The rationale behind the efficacy of MADs is that ad-
vancement of the mandible and tongue improves upper airway
patency during sleep by enlarging the upper airway and by
decreasing upper airway collapsibility [5, 6].
Barnes et al. [7] compared the effects of MAD treatment
with CPAP onmood disorders and depression in a randomized
placebo-controlled crossover trial and found no significant
differences between these two therapies in their improvement
of these disorders. Similar results were found by Engleman
et al. [8] in a randomized crossover trial in which the effects of
CPAP and MAD treatment on anxiety and depression symp-
toms were compared. To our best knowledge, no randomized
placebo-controlled trials have been performed comparing the
effects of an objectively titrated MAD and CPAP on symp-
toms of psychological distress. To enable an unbiased com-
parison between those treatment modalities, both treatments
should be titrated objectively. Further, the crossover design of
previous studies may have a risk of carry-over effects. The
primary aim of this randomized placebo-controlled trial was,
therefore, to compare the effects of an objectively titrated
MAD with those of nasal CPAP (nCPAP) and an intraoral
placebo appliance on symptoms of psychological distress in
a parallel design. The hypothesis was that there is no signifi-
cant difference between objectively titrated MAD and nCPAP
therapies in improving psychological distress symptoms in
mild/moderate OSA patients. To control for possible placebo
effects, an intraoral placebo device served as a passive control
condition for both active treatment modalities. It was hypoth-
esized that the intraoral placebo appliance would not signifi-
cantly improve psychological distress symptoms in mild/
moderate OSA patients. Following the hypothesis of Beebe
and Gozal [3], we also hypothesized that a significant corre-
lation between the amount of psychological distress and the
apnea-hypopnea index (AHI) values in the three therapy
groupswould occur. Therefore, the secondary aims of this trial
were (1) to determine the relation between the amount of
psychological distress and the AHI values at baseline in the
three therapy groups and (2) to determine the relation between
the amount of psychological distress at baseline and the
change of AHI over time in the three therapy groups.
Patients and methods
Setting and participants
This study is part of a randomized controlled trial (RCT), in
which three therapy groups (viz., MAD, nCPAP, and placebo)
were compared [9]. Eligible OSA patients, living in the greater
Amsterdam area, were referred to the Slotervaart Medical
Center by their family physician. All patients underwent a
thorough medical examination, including a full polysomno-
graphic (PSG) recording, at the Departments of Neurology,
Pulmonary Medicine, and ENT, as well as a thorough dental
examination at the Department of Oral Kinesiology of the
Academic Centre for Dentistry Amsterdam (ACTA). The
OSA patients were invited for participation in the study when
they fulfilled the following inclusion criteria: age >18 years,
an apnea-hypopnea index (AHI) between 5 and 45 events per
hour, and an Epworth sleepiness score (ESS) ≥10 or at least
two of the symptoms suggested by the American Academy of
Sleep Medicine Task Force, e.g., unrefreshing sleep and day-
time fatigue [1, 10]. The medical and dental exclusion criteria
are shown in Table 1 [9]. Exclusion of temporomandibular
disorders was based on a functional examination of the mas-
ticatory system [11, 12].
The baseline characteristics of the patients at the time of
therapy allocation are presented in Table 2. This study was
approved by the Slotervaart Medical Center’s Ethics
Committee (# U/1731/0326, U/2679/0326). Written informed
consent was obtained from all participants. This study has
been registered at www.clinicaltrials.gov (# NCT00950495).
Randomization and interventions
At the start of this RCT, consenting patients were allocated to
the interventions using block randomization. The allocation
sequence was automatically generated and concealed by an
Table 1 Number of patients excluded based on the medical and dental
exclusion criteria used in this study [9]




Respiratory/sleep disorder other than OSA 23
Body mass index >40 3
Medication usage that could influence
respiration or sleep
2
Periodic limb movement disorder 21
Previous treatment with CPAP or MAD –
Reversible morphological upper airway
abnormalities (e.g., enlarged tonsils)
17





Untreated periodontal problems 1
Dental pain –
Lack of retention possibilities for an oral
appliance
28
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independent co-worker. Three types of interventions were
used in this parallel-group study. First, an individually fabri-
catedMADwith an adjustable mandibular protrusion position
at a constant vertical dimension was used [13, 14]. Second,
nCPAP of the REMstar Pro system was used (Respironics,
Herrsching, Germany). Third, a thin (<1 mm), hard acrylic-
resin palatal splint with only a partial palatal coverage was
used as a placebo [15].
Both MAD and nCPAP were titrated before the start of the
treatment [9]. For the titration of the MAD, four ambulatory
polysomnographic (PSG) recordings were performed at regu-
lar time intervals of approx. 3 weeks. The total titration period
was approx. 10 weeks. The most effective protrusion position
of the MAD (i.e., the mandibular position that yielded the
lowest AHI value) was chosen from among four randomly
offered positions (viz., 0, 25, 50, and 75% of the maximum
protrusion). The MAD was set at 25% of the maximum pro-
trusion in 1 patient, at 50% in 7 patients, and at 75% in 12
patients [9]. For the placebo group, four ambulatory PSG re-
cordings were performed at regular time intervals similar to
the MAD group [16]. The titration of nCPAP was performed
during a PSG recording at the Slotervaart Medical Center. The
pressure was increased in steps of 1 cm H2O/hour, until the
AHI and respiration-related arousals were reduced to ≤5/hour,
and snoring was minimized. The average value of the pressure
was 7.3 (SD, 1.9; range, 4–11) cm H2O [9].
Procedure
During the titration period of approx. 10weeks, all the patients
visited ACTA four times at regular intervals, during which the
BMI (kg/m2) was determined and the Epworth sleepiness
scale (ESS) [10] was completed. The participants were also
interviewed (1) about their compliance (% of nights per week
of wearing), (2) about possible side effects (nature and num-
ber; determined in an open question) of the MAD during the
study period, and (3) about the change (increased, unchanged,
or decreased) in snoring intensity, based on information they
obtained from their bed partner. These outcomes have been
described in detail in Aarab et al. [13] and Aarab et al. [9].
From all the patients, two PSG recordings were obtained in
the sleep laboratory of the Slotervaart Medical Center: the first
one before treatment and the second one after 6 ± 2 months
(mean ± SD) for the therapy evaluation. The outcomes of
these PSG recordings are also described in detail in Aarab
et al. [9].
All patients filled out the Dutch version of the Symptom
Checklist-90-Revised (SCL-90-R) twice: the first one before
treatment and the second one at therapy evaluation. The SCL-
90-R is a multidimensional symptom inventory designed to
measure symptomatic psychological distress over the past
week (e.g., depression, anxiety, and somatization). Its reliabil-
ity and validity proved to be good for both the original and the
Table 2 Patient characteristics (mean ± SD) at baseline of the mandibular advancement device (MAD) group, nasal continuous positive airway










Normal values of Dutch
healthy population (n = 1004)
Age (years) 50.4 ± 8.9 54.0 ± 10.1 51.3 ± 9.6 49.3 ± 7.3 –
Number of man/woman 17/ 4 15/ 7 15/ 6 5/ 2 –
Apnea-hypopnea index 21.4 ± 11.0 20.1 ± 9.0 19.5 ± 8.4 14.8 ± 3.8 –
Epworth sleepiness score 12.0 ± 5.7 10.7 ± 4.4 10.8 ± 4.0 13.7 ± 1.9 –
Body mass index (kg/m2)a 27.1 ± 3.2 30.7 ± 3.7 31.1 ± 4.7 27.8 ± 4.1
SCL-90-R
Somatization 22.0 ± 10.3 24.6 ± 11.9 21.9 ± 10.8 24.3 ± 10.3 16.7 ± 5.3***
Insufficiency of thinking and acting 18.3 ± 7.6 18.7 ± 9.6 19.9 ± 9.5 19.0 ± 6.7 12.6 ± 4.3***
Interpersonal sensitivity 27.6 ± 10.4 26.9 ± 14.5 28.5 ± 17.7 26.3 ± 8.5 24.1 ± 7.6
Depression 26.3 ± 11.8 28.5 ± 15.3 30.5 ± 17.5 30.3 ± 15.8 21.6 ± 7.6***
Anxiety 14.9 ± 6.5 16.9 ± 9.6 15.6 ± 9.7 14.8 ± 5.6 12.8 ± 4.4*
Hostility 8.8 ± 3.7 9.2 ± 3.8 8.6 ± 4.6 8.8 ± 1.9 7.2 ± 2.1**
Agoraphobia 8.7 ± 3.0 9.3 ± 5.1 9.2 ± 6.7 7.5 ± 1.0 7.9 ± 2.3
Sleeping problems 7.6 ± 3.6 7.2 ± 3.8 8.4 ± 4.3 10.4 ± 4.6 4.5 ± 2.2***
Global severity index 149.3 ± 60.3 144.9 ± 68.1 162.0 ± 90.7 118.0 ± 38.2 118.3 ± 32.4*
P values as result of the one-sample t tests comparing the three therapy groups and the normal values in Dutch healthy population for the various
dimensions of the SCL-90-R: ***P < 0.001; **P < 0.01; *P < 0.05
aMAD patients had a significantly lower BMI than placebo and nCPAP patients (P = 0.002 and 0.006, respectively)
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Dutch version [17, 18]. Moreover, norm scores are available
for the Dutch general population [17].
Data analysis
The patient characteristics of the three therapy groups at base-
line, including the different dimensions of the SCL-90-R,
were compared using one-way analyses of variance, followed
by least-significant difference (LSD) pair-wise comparisons.
One-way analyses of variance were also used to detect differ-
ences in compliance between the three therapy groups [9]. For
the different dimensions of the SCL-90-R, one-sample t tests
were used to analyze differences between outcomes related to
the therapy groups and the normal values of the Dutch popu-
lation, and model assumptions were checked. For both the
per-protocol analysis and the intention-to-treat analysis, linear
mixed models were used to study the differences between the
groups for the different dimensions of the SCL-90-R over
time. In these models, the treatment group variable was intro-
duced as a dummy variable with the MAD group as reference
group. The difference between treatment groups over time
was studied by an interaction term of treatment times the time
variable. Pearson’s correlation was used to test the relation
between AHI values and the different dimensions of the
SCL-90-R.
All statistical tests were performed with the SPSS 21.0
(SPSS Inc., Chicago, IL) and SAS 9.3 (Statistical Analysis
System, SAS Institute Inc., Cary, NC, USA) software
packages.
Results
A total of 64 patients were enrolled in the study and were
randomized at the start of the RCT as shown in Fig. 1 [9].
Three patients in the nCPAP group terminated the treatment
before evaluation, because they experienced more side effects
than benefits out of their treatment. One patient in the placebo
group terminated the treatment, because of private reasons
unrelated to the study. Another patient in the placebo group
did not receive the placebo treatment, because of an urgent
medical condition that occurred after the allocation. Two other
OSA paents assessed for eligibility
n = 219
Paents enrolled for the study
n = 64
Assigned to Placebo n = 21Assigned to MAD n = 21 Assigned to nCPAP n = 22
Received MAD n = 21 Received Placebo n = 20
Did not receive Placebo n =1
Received nCPAP n = 22
Lost to follow-up n = 1 Disconnued intervenon n = 1Lost to follow-up n = 1
Disconnued intervenon n = 3
Completed follow-up n = 20 Completed follow-up n = 18 Completed follow-up n = 19
Medical exclusion criteria n = 73
Dental exclusion criteria n = 29
Refused to parcipate n = 31
Could not be reached n = 22
Fig. 1 Flow-chart of the patients
through each stage of the trial.
MAD mandibular advancement
device, nCPAP nasal continuous
positive airway pressure
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patients, one in the nCPAP group and another in the MAD
group, could not be reached after the random allocation and
could thus not be evaluated. Hence, 57 patients completed the
entire study protocol.
The patient characteristics at baseline are presented in
Table 2. BMI was the only baseline characteristic that differed
between the three therapy groups (F = 5.170; P = 0.008). LSD
analyses revealed that the MAD group had a significantly
lower BMI than the placebo and nCPAP groups (P = 0.002
and 0.006, respectively) [9]. The mean (±SD) baseline values
of the different dimensions of the SCL-90-R of the three ther-
apy groups, of the drop-outs, and of the normal values of the
Dutch healthy population are also shown in Table 2. The
baseline values of the different dimensions did not differ sig-
nificantly between the three therapy groups (P = 0.305–0.987;
Table 2). Further, the baseline values of the SCL-90-R of the
drop-outs were not different from those of the therapy groups
either (P = 0.348–0.997). The three groups showed higher
average values of psychological distress at baseline than the
reported normal values for the Dutch population in the dimen-
sions Bsomatization,^ Binsufficiency of thinking and acting,^
Banxiety,^ Bhostility,^ Bdepression,^ Bsleeping problems,^
and Bglobal severity index^ (T = 6357–2.566; P = 0.000–
0.013; Table 2).
The mean (±SD) baseline values of the different dimen-
sions of the SCL-90-R of the three therapy groups who com-
pleted the entire study protocol as well as the changes in these
variables from baseline to therapy evaluation are shown in
Table 3. As a result of missing values in the different dimen-
sions of the SCL-90-R per therapy group, the number of ob-
servations used in the per-protocol analyses varied per dimen-
sion (see Table 3). The MAD group showed significant
improvements over time in the dimensions Bsomatization,^
Binsufficiency of thinking and acting,^ Bagoraphobia,^
Banxiety,^ Bsleeping problems,^ and the Bglobal severity
index^ (F = 4.01–15.47, P = 0.048–0.000, Table 3). These
improvements in symptoms were, however, not significantly
different from the improvements in symptoms observed in the
nCPAP and placebo groups (P = 0.374–0.953). The intention-
to-treat analysis showed similar results as the per-protocol
analyses: the MAD group showed significant improvements
over time in the dimensions Bsomatization,^ Binsufficiency of
thinking and acting,^ Bagoraphobia,^ Banxiety,^ Bsleeping
problems,^ and the Bglobal severity index^ as well
(F = 4.01–16.34, P = 0.025–0.000), while these improve-
ments were not significantly different from those observed
in the nCPAP and placebo groups (P = 0.175–0.950).
The MAD group had used their appliance 90.6% (SD,
13.3) of the nights; the nCPAP group 82.9% (SD, 27.2) of
the nights; and the placebo group 93.9% (SD, 15.7) of the
nights. No significant group differences in compliance were
found (F = 1.518, P = 0.228) [9].
There was no significant correlation between the baseline
AHI value and the baseline values of the different dimensions
of the SCL-90-R in the three groups (P = 0.121–0.888). A
significant correlation was found between the baseline values
of the Bglobal severity index^ and the changes in AHI values
(ΔAHI) between baseline and therapy evaluation in both the
MAD and nCPAP group (P = 0.025). Patients with higher
values of the Bglobal severity index^ at baseline showed less
reduction in the AHI than patients with lower values of this
index at baseline (Fig. 2). In the placebo group, there was no
significant correlation between BΔAHI^ and the baseline
values of Bglobal severity index^ (P = 0.615).
Table 3 The mean (±SD) baseline and therapy evaluation values of the different dimensions of the SymptomChecklist-90-Revised (SCL-90-R) of the
mandibular advancement device (MAD) group, nasal continuous positive airway pressure (nCPAP) group, and placebo group in the per-protocol
analyses
Dimension (number of observations used) MAD (n = 20) P* nCPAP (n = 18) Placebo (n = 19) P*
Baseline Therapy Baseline Therapy Baseline Therapy
Somatization (n = 107) 22.0 ± 10.3 17.7 ± 5.5 0.000** 24.6 ± 11.9 21.3 ± 11.5 21.9 ± 10.8 17.9 ± 7.9 0.374
Insufficiency of thinking and acting* (n = 104) 18.3 ± 7.6 15.8 ± 5.7 0.003** 18.7 ± 9.6 17.7 ± 10.0 19.9 ± 9.5 16.3 ± 8.1 0.646
Interpersonal sensitivity (n = 102) 27.6 ± 10.4 25.3 ± 8.4 0.206 26.9 ± 14.5 27.3 ± 14.8 28.5 ± 17.7 25.4 ± 15.4 0.953
Depression (n = 96) 26.3 ± 11.8 24.0 ± 7.1 0.056 28.5 ± 15.3 25.4 ± 16.4 30.5 ± 17.5 23.8 ± 6.5 0.445
Anxiety (n = 104) 14.9 ± 6.5 12.9 ± 4.2 0.033** 16.9 ± 9.6 15.2 ± 9.1 15.6 ± 9.7 14.1 ± 6.8 0.573
Hostility (n = 106) 8.8 ± 3.7 8.7 ± 3.3 0.437 9.2 ± 3.8 8.9 ± 3.8 8.6 ± 4.6 7.5 ± 2.6 0.521
Agoraphobia (n = 103) 8.7 ± 3.0 7.7 ± 1.1 0.028** 9.3 ± 5.1 7.8 ± 1.9 9.2 ± 6.7 8.9 ± 5.5 0.479
Sleeping problems (n = 106) 7.6 ± 3.6 6.3 ± 3.0 0.048** 7.2 ± 3.8 6.1 ± 2.5 8.4 ± 4.3 7.4 ± 3.3 0.792
Global severity index (n = 85) 149.3 ± 60.3 132.9 ± 38.2 0.018** 144.9 ± 68.1 137.7 ± 66.2 162.0 ± 90.7 124.1 ± 24.0 0.387
*P value as result of the linear mixed model analyses for the time effect within the MAD group
**Statistically significant at the 0.05 probability level
***P value as result of the linear mixed model analyses comparing the three groups over time
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Discussion
Both MAD and nCPAP showed significant improvements of
symptoms of psychological distress after 6 months of treat-
ment. However, these significant improvements were not dif-
ferent from those observed in the placebo group.
In randomized clinical trials, there are often problems of
noncompliance, where the patient does not adhere to the
assigned treatment or does not complete questionnaires as
we also observed in this study. Typically, this leads to esti-
mates that can potentially be biased when the probability of a
missing value is related to the characteristics of the patients.
Further, missing data can also lead to a reduction of statistical
power [19]. To overcome this problem, linear mixed model
analysis can be used. Themajor strengths of mixed models are
their ability to accommodate missing data points often en-
countered in longitudinal datasets and to generate valid study
results [20]. Therefore, we used linear mixed model analyses
in this study.
The population in the present study showed higher average
values of psychological distress at baseline than the reported
normal values for the Dutch population. The relationship be-
tween OSA and psychiatric disorders, especially depression,
has already been studied for decades [21]. Pillar and Lavie
[22] reported in their male population that neither the presence
nor the severity of OSA was associated with depression or
anxiety. On the other hand, recent evidence has confirmed
important connections between OSA and psychiatric disor-
ders. Psychiatric co-morbidity in OSA patients was examined
in a large retrospective chart review of more than 100,000
veterans. A significantly higher prevalence of numerous
psychiatric disorders, including depression and anxiety, was
found in OSA patients as compared to non-OSA patients [23].
Others reported depression symptoms in 17–41% of OSA
patients [24, 25]. Harris et al. [2] suggested that direct treat-
ment of depression in OSA patients might improve acceptance
of therapy, reduce sleepiness and fatigue, and improve quality
of life, but that intervention trials are needed to answer this
question. Although the causal relationship between symptoms
of psychological distress and OSA has not been determined
yet, a higher prevalence of these symptoms in OSA patient
seems to be a consistent finding, which corresponds with our
results.
All patients who completed the trial showed relatively high
compliance rates of approx. 90% (i.e., the percentage of nights
per week usage). This relatively high compliance may be ex-
plained by the fact that during the study period the patients
frequently visited ACTA to be interviewed about the frequen-
cy of wearing. This regular contact with the examiner could
have motivated the patients to use their appliances frequently
[9]. Although self-reported compliance has been suggested to
overestimate the actual use ofMADs, covert compliancemon-
itoring has shown excellent agreement between subjective and
objective compliance [26, 27].
The MAD effects on the OSA condition have been com-
pared with those of CPAP in several randomized clinical trials
[4]. Although in most previous crossover studies MADs were
considered less effective in reducing the AHI value than
CPAP in mild-to-moderate OSA patients, similar improve-
ments in subjective outcomes, such as excessive daytime
sleepiness and quality of life, were found [8, 28–30].
Further, it should be noted that these studies also indicated
Fig. 2 Scatterplot of the
correlation between the baseline
values of the Bglobal severity
index^ and the changes in AHI
values between baseline and
therapy evaluation (ΔAHI) in
both theMADand nCPAP groups
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that, in general, patients find MADs as a more acceptable
treatment compared to CPAP. In recent RCTs with a parallel
design, no significant differences between MAD and nCPAP
were reported in the subjective outcomes [9, 31]. Aarab et al.
[9] found no significant difference in efficacy between MAD
and CPAP in mild-to-moderate cases. Although Doff et al.
[31] showed that CPAP was more effective in lowering the
AHI than MAD in a group of mild to severe OSA patients,
they found no significant differences between both treatments
in the proportions of successful treatments. A recent meta-
analysis showed that CPAP is more effective in lowering
AHI than MAD in moderate-to-severe OSA patients; howev-
er, the superiority of CPAP over MAD is hypothesized to be
less in mild cases [32]. Further, a recent crossover study by
Phillips et al. [33] showed that important health outcomes
were similar after 1 month of optimal MAD and CPAP treat-
ment in patients with moderate-to-severe OSA. Thus, the out-
comes of our study are in line with previous findings wherein
both MAD and nCPAP show comparable treatment results in
a group of mild-to-moderate OSA patients.
Beebe and Gozal [3] suggested that both intermittent hyp-
oxia and sleep disruption induce dysfunction of the prefrontal
regions of the brain cortex, which may predispose to mood
disorders. Following this hypothesis, at baseline, we
suspected a significant correlation between the amount of psy-
chological distress and the AHI values. However, we did not
find this correlation. On the other hand, OSA patients with
higher values of the psychological distress at baseline showed
less reduction in the AHI than patients with lower values of
this index at baseline. The nature of this association is unclear,
but this finding suggests that the level of psychological dis-
tress at the start of the treatment may play a significant role in
the treatment outcome.
In this study, the significant improvements in symptoms of
psychological distress in the MAD and nCPAP groups were
not better than those observed in the placebo group. This is in
line with our previous findings wherein we reported signifi-
cant improvements in the Epworth sleepiness scale (ESS) and
the Short-Form General Health Survey (SF-36) in all three
groups without any differences in effects between the three
therapy groups [9]. These placebo effects on excessive day-
time sleepiness were also shown in a recent study, in which the
effects of MAD were compared with an intraoral placebo
splint in mild-to-moderate OSA patients [34]. Power calcula-
tion was performed for the primary outcome variable of this
randomized placebo-controlled trial, viz., the AHI [9]. No
power calculations were performed for the secondary outcome
variables (viz., ESS, SF-36, and SCL-90-R). Therefore, our
sample size per therapy group may have not been sufficient to
find a significant difference between the therapy groups in the
change of the different dimensions of SCL-90-R. However,
our findings correspond with many previous, well-designed
studies [7, 28, 35, 36] in which it was also reported that most
of their OSA patients obtained a significant benefit in neuro-
psychological function andmood from their placebo treatment
compared to MAD and CPAP treatments. These observed
improvements in symptoms of psychological distress may
be due to extensive attention given to the patients during the
entire protocol, to a change in lifestyle as a result of the infor-
mation given to the patients at baseline, and/or to a placebo
response. Further, the high initial values of the SLC-90-R
scores at baseline result in a higher possibility of decreases
in these scores over time. The tendency of high values to
return towards an individual’s more typical average state is
known as Bregression to the mean.^ Stepnowsky et al. [37]
reported in a recent study that baseline emotional distress pre-
dicted the drop in AHI in response to placebo treatment.
Highly distressed patients showed a greater placebo response
with a 34% drop in AHI. Although we could not confirm this
in our study, all these findings together support the importance
of including a placebo treatment in a randomized controlled
trial design to determine unbiased treatment effects.
Within the limits of this study, it can be concluded
that there is no significant difference between MAD,
nCPAP, and an intraoral placebo appliance in their ben-
eficial effects on symptoms of psychological distress in
mild-to-moderate OSA patients. Further, this study sug-
gests that the level of psychological distress at the start
of the treatment may play a significant role in the treat-
ment outcome of MAD and nCPAP in a group of mild-
to-moderate OSA patients.
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